Endocrinologists at Imperial NHS Trust in the UK are planning a clinical study focused on Kisspeptin administration to Kallmann syndrome / CHH females under 35 years of age.
The study will be based at Charing Cross Hospital in London and will involve three separate day visits to the hospital. Food will be provided during the visit as well as travel costs and attendance payment.
Kisspeptin is a hormone that directly affects the hypothalamus and normally allows the correct release of GnRH and has the potential to be used in the treatment of Kallmann syndrome / CHH both for hormone replacement and for fertility treatments.
The study aims to find the best method of using Kisspeptin in the treatment of infertility in females.
For further information please contact:
Dr Bijal Patel.
bijal.patel@imperial.ac.uk
